Merck drops out of a $125M KRAS alliance with Moderna, taking a step away from the Covid-19 star
Four years ago, Merck’s Roger Perlmutter lined up to pay Moderna an extra $125 million for preferred equity to gain rights to its early stage KRAS program for mRNA-5671. But now that deal is over.
Moderna noted the transition in its Q4 report today, noting that it regained all rights to the therapy and is now considering “next steps.” The company added:
The Phase 1 open-label, multi-center study to evaluate the safety and tolerability of mRNA-5671 both as a monotherapy and in combination with pembrolizumab (Keytruda), led by Merck, is ongoing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.